Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Group LLC in a research note issued to investors on Thursday. They presently have a $18.00 price target on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 29.59% from the company’s current price. Jefferies Group also issued estimates for Valeant Pharmaceuticals International’s Q3 2017 earnings at $0.83 EPS, Q4 2017 earnings at $0.80 EPS, FY2017 earnings at $3.45 EPS, FY2018 earnings at $3.33 EPS, FY2019 earnings at $3.85 EPS, FY2020 earnings at $4.49 EPS and FY2021 earnings at $5.10 EPS.
Other equities research analysts have also issued reports about the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Vetr lowered shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.94 target price on the stock. in a report on Monday, May 15th. Guggenheim started coverage on shares of Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 target price on the stock. BidaskClub upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Thursday, June 29th. Finally, Cantor Fitzgerald set a $23.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $17.31.
Valeant Pharmaceuticals International (NYSE:VRX) traded up 0.58% during trading on Thursday, reaching $13.89. 12,747,107 shares of the company’s stock traded hands. The company’s market cap is $4.84 billion. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74. The firm’s 50 day moving average is $16.57 and its 200 day moving average is $13.38.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period last year, the business posted ($0.88) earnings per share. Analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. ValueAct Holdings L.P. increased its position in shares of Valeant Pharmaceuticals International by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock worth $198,509,000 after buying an additional 3,002,963 shares during the period. Vanguard Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 4.2% in the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock worth $125,853,000 after buying an additional 294,643 shares during the period. Bank of Montreal Can increased its position in shares of Valeant Pharmaceuticals International by 9.8% in the second quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock worth $109,521,000 after buying an additional 564,215 shares during the period. OppenheimerFunds Inc. increased its position in shares of Valeant Pharmaceuticals International by 17.1% in the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock worth $49,516,000 after buying an additional 656,116 shares during the period. Finally, CIBC World Markets Inc. increased its position in shares of Valeant Pharmaceuticals International by 2.3% in the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock worth $64,726,000 after buying an additional 83,592 shares during the period. 51.14% of the stock is owned by institutional investors.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
